ESR1 Mutation Test: Breast Cancer, Hormone Therapy Resistance, and Results

An ESR1 mutation test looks for acquired changes in the gene that encodes estrogen receptor alpha. In hormone receptor-positive, HER2-negative metastatic breast cancer, activating ESR1 mutations can emerge under pressure from aromatase inhibitor therapy and allow the cancer to keep using estrogen-receptor signaling even when estrogen levels are suppressed. Detecting one of these mutations may help select a different endocrine treatment, including an oral selective estrogen receptor degrader in an appropriate patient. Plasma circulating tumor DNA is often the preferred specimen because ESR1 mutations may differ among metastatic sites and can change over time. Tissue testing remains useful when blood testing is negative, when a biopsy is needed for other reasons, or when the tumor’s receptor status is uncertain. ESR1 testing is mainly a metastatic-disease biomarker; mutations are uncommon in untreated primary breast cancers. The result must identify the exact variant and be interpreted with prior endocrine therapy, current disease burden, other actionable mutations, and the full treatment history.

• ESR1 mutations most often develop after exposure to aromatase inhibitors in advanced hormone receptor-positive breast cancer.
• Plasma ctDNA is commonly used because it can capture mutations shed from several metastatic sites.
• A detected activating ESR1 mutation suggests resistance to estrogen-deprivation therapy, not resistance to every endocrine treatment.
• A negative plasma result can be falsely reassuring when tumor DNA shedding is low.
• Common hotspot variants include D538G, Y537S, Y537N, Y537C, E380Q, and L536 substitutions.

Table of Contents

• What ESR1 Mutations Do
• When Testing Is Used
• Blood, Tissue, and Test Methods
• How to Interpret Results
• Treatment Implications
• Repeat Testing and Disease Evolution
• Limitations and Questions to Ask

What ESR1 Mutations Do

ESR1 provides instructions for estrogen receptor alpha, a protein that enters the cell nucleus and controls genes involved in breast-cell growth. In a normal hormone-responsive cell, estrogen binds the receptor and activates it. Many breast cancers remain dependent on this pathway, which is why endocrine treatments can be effective for years.

Aromatase inhibitors reduce estrogen production. In metastatic disease, prolonged estrogen deprivation can select tumor cells with ESR1 mutations that keep the receptor active even when little estrogen is present. These are usually somatic mutations acquired by the cancer, not inherited changes present in every cell. They do not by themselves imply a hereditary breast cancer syndrome or create a reason to test healthy relatives.

Most clinically important ESR1 mutations occur in the ligand-binding domain, particularly codons 536 through 538. Common examples include p.D538G and substitutions at p.Y537. E380Q is another recurrent alteration. The exact variant can affect how strongly the receptor remains active and how well a drug suppresses it, although treatment decisions are generally based on the broader category of an activating ESR1 mutation rather than one hotspot alone.

ESR1 amplification and ESR1 fusion events are different findings. They may appear on comprehensive profiling reports, but evidence for treatment selection is not the same as for well-established activating ligand-binding-domain mutations. A report should distinguish mutation, amplification, fusion, and simple estrogen-receptor protein positivity.

The test also differs from immunohistochemistry for estrogen receptor. Pathology staining asks whether tumor cells express ER protein, usually reported as a percentage and intensity. ESR1 sequencing asks whether the receptor gene carries an acquired activating change. A tumor can remain ER-positive by immunohistochemistry while carrying an ESR1 mutation that changes response to specific endocrine treatments.

Broad testing often evaluates ESR1 alongside PIK3CA, AKT1, PTEN, ERBB2, BRCA1, BRCA2, and other genes. A separate PIK3CA mutation test may identify another actionable pathway, and more than one target can coexist. Treatment planning therefore uses the complete molecular profile rather than ranking every mutation as if only one can matter.

When Testing Is Used

ESR1 testing is most useful in hormone receptor-positive, HER2-negative metastatic or advanced breast cancer after the tumor has been exposed to endocrine therapy. Testing can be performed at progression or when a new endocrine treatment is being selected. Current guidance supports testing for ESR1 mutations when the result could determine eligibility for an ESR1-directed endocrine option.

Routine testing at the initial diagnosis of an untreated early-stage breast cancer is usually low yield because ESR1 hotspot mutations are rare before endocrine selection pressure. Testing may become relevant later if the cancer recurs after adjuvant aromatase inhibitor therapy, especially when the recurrence is metastatic and another endocrine line is being considered.

Common clinical situations include:

• Progression during or after an aromatase inhibitor plus a CDK4/6 inhibitor
• Metastatic recurrence after prior adjuvant aromatase inhibitor treatment
• Selection of endocrine therapy after one or more prior metastatic regimens
• A need to reassess several biomarkers from one blood sample
• Discordant behavior suggesting that the tumor’s biology has evolved
• Enrollment in a trial of an oral selective estrogen receptor degrader or other ER-targeted agent

Testing should not be ordered in isolation from the treatment history. An ESR1 mutation detected before any aromatase inhibitor exposure is unusual and may prompt confirmation, review of prior therapies, or evaluation of sample identity. Conversely, a patient with years of aromatase inhibitor exposure may still have ESR1 wild-type disease and another resistance mechanism.

The timing can matter. A mutation may become detectable in plasma months before imaging shows clear progression, but routine switching solely on molecular rise remains a specialized strategy. The PADA-1 trial showed that early switching from an aromatase inhibitor to fulvestrant while continuing palbociclib after rising ESR1-mutant ctDNA could delay progression in a defined trial population. That approach does not mean every positive low-level result should trigger an automatic change; the current regimen, available drugs, symptoms, imaging, and guideline context must be considered.

A liquid biopsy cancer test may be ordered as a broad panel rather than an ESR1-only assay. This can be efficient when the same blood draw is also used to look for PIK3CA, AKT1, ERBB2, BRCA reversion changes, or other treatment-relevant alterations.

Blood, Tissue, and Test Methods

Plasma is commonly preferred for ESR1 mutation testing. Tumor cells release fragments of DNA into the bloodstream, and a blood sample can capture mutations from more than one metastatic site. This matters because resistance can be heterogeneous: one lesion may carry Y537S while another carries D538G, and several ESR1 variants may coexist in the same patient.

A plasma result is affected by how much tumor DNA is present. Liver and extensive bone or soft-tissue disease may shed measurable ctDNA, while low-volume disease or disease limited to the brain, pleura, or bone can produce a low tumor fraction. A negative result in a low-shedding situation does not exclude an ESR1 mutation.

Tissue testing uses DNA from a metastatic biopsy or archived tumor. A recent metastatic specimen is generally more informative than the original untreated breast tumor because ESR1 mutations often emerge later. Tissue can also confirm estrogen receptor, progesterone receptor, and HER2 status and identify histologic change. Its limitation is sampling only one site at one time.

Common test methods include:

• Digital droplet PCR: Highly sensitive for a defined set of common hotspots but cannot identify variants outside the assay menu.
• Targeted real-time PCR: Rapid and practical for selected mutations, with similar limitations in coverage.
• DNA-based NGS: Evaluates many ESR1 variants and other genes in one assay.
• Error-corrected plasma NGS: Uses molecular barcodes and deep sequencing to improve confidence at low VAF.
• RNA sequencing: May help characterize rare ESR1 fusions but is not the standard method for common hotspot mutations.

The report should state which exons and codons were tested, the limit of detection, and whether the assay is validated for plasma, tissue, or both. A negative “hotspot” assay is not equivalent to a negative comprehensive ESR1 analysis if the patient has a rare variant outside the covered positions.

Variant allele frequency is often low in plasma. A true ESR1 mutation at 0.2% VAF can be clinically meaningful when the assay is validated at that level and quality controls are met. The absolute VAF should not be used as a direct measure of tumor size because shedding, treatment, metastatic location, and total cell-free DNA vary.

Blood should be drawn into the collection tubes specified by the laboratory. Delayed processing in an ordinary tube can cause white blood cells to release genomic DNA and dilute ctDNA. No fasting is required. Biotin, vitamins, and food do not alter the DNA sequence result.

When tissue and plasma disagree, the more recent and biologically representative specimen often receives greater weight. A positive plasma result can reveal a mutation absent from one tissue biopsy because another metastatic clone is shedding it. A negative plasma result with a positive tissue result may simply reflect low ctDNA at the blood-draw time.

How to Interpret Results

A useful ESR1 report names the exact alteration and classifies whether it is activating and clinically actionable. “ESR1 mutation detected” without the variant and assay details is incomplete. The oncology team should also review other findings and the tumor fraction estimate.

Result	Likely meaning	Typical clinical response
Activating ligand-binding-domain mutation detected	Acquired endocrine resistance mechanism, especially after aromatase inhibitor exposure	Consider ESR1-directed endocrine treatment and review other actionable biomarkers
Several ESR1 mutations detected	Polyclonal resistance arising in different tumor subclones	Choose therapy based on the class of alteration and overall clinical setting
No ESR1 mutation detected with adequate ctDNA	No reportable ESR1 mutation at that time	Use other biomarkers and clinical factors to select therapy
No ESR1 mutation detected with low tumor fraction	Indeterminate negative because the blood may contain too little tumor DNA	Consider tissue testing or repeat plasma testing when it would change treatment
ESR1 variant of uncertain significance	Unknown effect on receptor activity or drug response	Do not use alone to choose an ESR1-directed drug

An activating ESR1 mutation does not mean all endocrine therapy will fail. It mainly indicates resistance to strategies that depend on depriving the receptor of estrogen, such as aromatase inhibition. Selective estrogen receptor degraders and some other agents can inhibit or reduce the mutant receptor through different mechanisms. Sensitivity is not identical across drugs or variants, so current evidence matters.

A negative result does not prove endocrine sensitivity. The tumor may resist through loss of ER expression, activation of the PI3K-AKT-mTOR pathway, ERBB2 changes, cell-cycle alterations, growth-factor receptor signaling, or lineage plasticity. The biopsy may also show that the cancer has become hormone receptor-negative. Molecular testing complements pathology rather than replacing it.

Coexisting variants guide competing or sequential options. PIK3CA, AKT1, or PTEN alterations may support pathway-targeted treatment. Germline or somatic BRCA1/2 findings can influence PARP inhibitor use. ERBB2 mutations or HER2-low protein expression can open other treatment pathways. The clinician weighs prior therapy, organ function, pace of disease, symptoms, and toxicity, not only mutation status.

A result near 50% VAF in plasma is not automatically germline. ESR1 hotspot mutations are usually somatic and can reach high VAF when the tumor fraction is high or there is copy-number imbalance. Germline ESR1 variants associated with estrogen resistance syndromes are rare and occur in a different clinical context.

Treatment Implications

The best-established treatment implication is selection of an endocrine agent that can remain active against an ESR1-mutant receptor. Elacestrant is an oral selective estrogen receptor degrader with evidence in previously treated ER-positive, HER2-negative advanced breast cancer, particularly in tumors with ESR1 mutations after prior endocrine therapy and CDK4/6 inhibition. Eligibility and preferred sequencing depend on the current label, guideline, prior therapies, and patient factors.

Fulvestrant is an injectable selective estrogen receptor degrader and may retain activity in some ESR1-mutant cancers, although specific variants such as Y537S can show reduced sensitivity in laboratory and clinical data. It may be combined with targeted agents when another pathway alteration is present. New oral SERDs, complete estrogen receptor antagonists, proteolysis-targeting therapies, and other ER-directed drugs continue to be evaluated and may become available through approvals or clinical trials.

An ESR1 result should be interpreted alongside how long the previous endocrine regimen controlled disease. A patient whose cancer remained controlled for years on an aromatase inhibitor plus a CDK4/6 inhibitor may still have endocrine-responsive biology even after an ESR1 mutation emerges. A patient with rapid progression through several endocrine lines and organ-threatening disease may need chemotherapy or an antibody-drug conjugate rather than another endocrine monotherapy.

The presence of visceral metastases does not automatically exclude endocrine treatment. The clinically important distinction is often whether there is a visceral crisis or impending organ failure that requires a faster response. Liver metastases that are stable and asymptomatic differ from rapidly worsening bilirubin, respiratory compromise, or severe marrow failure.

The mutation can also influence whether continuing an aromatase inhibitor makes sense. Once an activating ESR1 mutation is driving progression, further estrogen deprivation alone is unlikely to overcome the mechanism. Switching the endocrine backbone or moving to a different treatment class is generally more rational than simply changing from one aromatase inhibitor to another.

Treatment combinations require attention to toxicity. Oral SERDs can cause nausea, fatigue, appetite changes, musculoskeletal symptoms, or lipid abnormalities, depending on the agent. PI3K, AKT, or mTOR inhibitors add distinct risks such as hyperglycemia, rash, diarrhea, stomatitis, or pneumonitis. Drug selection should account for diabetes, liver function, prior adverse effects, and patient preference.

An ESR1 mutation is a predictive biomarker, not a guarantee of response. Some tumors depend on multiple pathways, and resistant subclones can coexist. Imaging, symptoms, laboratory tests, and tumor markers remain necessary after treatment begins.

Repeat Testing and Disease Evolution

ESR1 mutations are dynamic. A mutation may be absent in the original tumor, appear after aromatase inhibitor exposure, decline when an effective treatment suppresses the clone, and rise again at later progression. Several variants may emerge in parallel, creating polyclonal resistance.

Repeat testing is reasonable when the result could change the next treatment and the prior assay is old or incomplete. It may be especially useful after another line of endocrine therapy, when disease progression occurs years after the last molecular profile, or when a new oral SERD requires documented ESR1 mutation status.

A rising mutation level is not the same as radiographic progression. ctDNA can change earlier than scans, but analytical variation, total cfDNA, and treatment timing affect VAF. Serial values are most comparable when measured by the same assay. Decisions based on molecular progression alone should follow evidence-based protocols rather than an isolated rise.

After treatment with an ESR1-directed agent, progression testing may reveal persistence of the same mutation, additional ESR1 mutations, growth of a PI3K-pathway clone, ERBB2 changes, or complete loss of detectable ctDNA. A broad tumor molecular profiling test may be more useful than repeating an ESR1-only test at that point.

Tissue biopsy remains important when the biology appears to change. Loss of ER staining, gain of HER2 expression, transformation to a different histologic pattern, or a second primary cancer can alter treatment more than one plasma mutation. A biopsy can also provide material for clinical trials and research biomarkers.

Timing around treatment matters. A blood draw soon after starting therapy can show transient ctDNA changes from tumor-cell death. A sample drawn when disease burden is very low may be negative even though resistant cells remain. The oncology team should document the date of the last dose, imaging findings, and reason for the test.

Patients should keep every molecular report. Future eligibility may depend on the exact variant, specimen date, prior drug exposure, and assay. A portal summary that says “ESR1 positive” may not contain enough detail for a later trial.

Limitations and Questions to Ask

The main limitation of plasma testing is a false-negative result from low ctDNA. The report may include a tumor fraction estimate, maximum somatic allele frequency, or statement that ctDNA was not detected. A negative test with no other tumor-derived variants is less reassuring than a negative ESR1 result in a sample with several known tumor mutations.

Coverage is another limitation. Some rapid assays test only D538G and a few Y537 variants. Rare but activating mutations at L536, E380, or other positions may be missed. The laboratory’s variant list and limit of detection should be reviewed when the clinical suspicion remains high.

Clonal hematopoiesis rarely creates a major ESR1 interpretation problem because ESR1 is not a common blood-clone gene. Still, plasma panels can contain unrelated blood-derived variants in genes such as DNMT3A, TET2, or TP53. Those findings should not be mistaken for breast-cancer mutations without appropriate filtering.

A tissue result can be limited by age and site. Testing the primary tumor removed ten years earlier may accurately show the original cancer but miss acquired metastatic resistance. Testing one progressing lesion can miss mutations present elsewhere. Plasma and tissue are complementary rather than competing methods.

Useful questions for the oncology team include:

• Is this an activating ESR1 mutation or a VUS?
• Was tumor DNA clearly detectable in the plasma sample?
• Which ESR1 hotspots and exons did the assay cover?
• Was the test performed after enough aromatase inhibitor exposure for an acquired mutation to be plausible?
• Are PIK3CA, AKT1, PTEN, BRCA1/2, and ERBB2 results also available?
• Does the result meet the current criteria for an oral SERD or a clinical trial?
• Would a metastatic biopsy change treatment or confirm receptor status?
• When should imaging and clinical response be assessed after treatment starts?

A test should answer a treatment question, not simply add another data point. The most useful ESR1 result is one obtained at the right disease stage, with adequate ctDNA or representative tissue, and reviewed alongside the full endocrine history.

References

• Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update 2023 (Guideline)
• ESR1 mutations in HR+/HER2- metastatic breast cancer 2023 (Review)
• Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial 2022 (RCT)
• Elacestrant Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial 2022 (RCT)
• Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups 2024 (Clinical Study)
• Standardized molecular pathology workflow for ctDNA-based ESR1 testing in metastatic breast cancer 2024 (Position Statement)

Disclaimer

ESR1 results should be interpreted by an oncology team using the exact variant, specimen type, prior endocrine therapy, disease burden, and other biomarkers. Treatment indications and preferred sequencing can change as new evidence and approvals emerge. Rapidly worsening pain, breathing difficulty, jaundice, confusion, or other signs of organ compromise require urgent medical assessment.